Background: The world Health Organization has declared hepatitis C a global health problem, with approximately 3 % of the worldﹶs population. HCV infection was associated with a high risk of CHD. Hs-CRP and fibrinogen was considered as markers of coronary artery disease, their elevation correlated with incidence of CAD, However Apo A deficiency predict future risk of CAD. Aim: To study correlation between HCV infections and marker risk factors of coronary heart disease in different stages of liver disease. Patients & Method: Forty three chronic HCV patients were recruited at specialized hepatology clinic in National Hepatology and Tropical Medicine Research Institute (NHTMRI),Cairo; they were classified into 3 groups according to Child – Pugh score (A, B, C), 42 % were Child class A, 28 % Child B and 30 % Child C, age from 20 to 80 years. 15 healthy subjects served as control group. Detection of the following tests occurred for both groups: Liver function tests: ALT, AST, ALP, total protein, albumin, bilirubin, GGT and AFP. Ultra sensitive CRP, fibrinogen, apoprotein A and Lipid profile: Total Cholesterol, triglyceride, HDL-C, LDL-C, and Total Lipid. Results: the data obtained from results show that :liver enzymes AST, ALT, total bilirubin, albumin, total protein and INR levels were significantly different between groups and control (p< 0.05), Alkaline phosphates, GGT and AFP levels were not differing significantly in study groups and control (p> 0.05). Cardiac enzymes; CK and LDH levels were not significantly different between groups and control (p> 0.05). The APO A levels were not differs significantly in study groups and controls (p> 0.05). The fibrinogen andhs-CRP levels in the patients appeared to be significantly higher than those in the healthy controls (p< 0.05). Conclusion: hs-CRP and fibrinogen may be considered as a CHC progression prognostic factor, Evidence indicates that hepatitis C virus (HCV) have a key role in coronary heart disease.
Published in | Clinical Medicine Research (Volume 3, Issue 2) |
DOI | 10.11648/j.cmr.20140302.18 |
Page(s) | 44-49 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2014. Published by Science Publishing Group |
Fibrinogen, Cardiovascular Disease, Hs-CRP, Hepatitis C Virus, APO A
[1] | Mohamed M.K. (2004). Epidemiology of HCV in Egypt 2004. The Afro-Arab Liver Journal 3(2): 41-52. |
[2] | Fallahian F, Najafi A. (2011). Epidemiology of hepatitis C in the Middle .EastSaudi J Kidney Dis Transpl.; 22(1):1-9. |
[3] | Vassalle C, Masini S, Bianchi F, Zucchelli GC. (2004). Evidence for association between Hepatitis C virus seropositivityu and coronary artery disease.Heart 90:565-566. |
[4] | Vassilios Papadopoulos1, Zafiris Kartasis2, Konstantinos Mimidis1, Stephanos Papantoniou1, et al., (2000) .Evaluation of haemostasis impairment in early stages of liver cirrhosis: a clinical study. J Mol Diagn. 2(3): 158–166. |
[5] | Guido M, Mangia A, Faa G; (2011). Chronic viral hepatitis: the histology report. Dig Liver Dis.; 43 Suppl 4:S331-43. |
[6] | Gumber, SC. and Chopra, S. (1995): Hepatitis C: a multifaceted disease. Review of extra hepatic manifestations. Ann Intern Med. 123:615-620. |
[7] | El-Serag, HB., Hampel, H. and Yeh, C. (2002): Extra hepatic manifestations of hepatitis among United States male veterians. J Hepatol. 36:1439-45. |
[8] | Forde K A, Kevin H, Andrea B T, Stacey T, et al., (2012). Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. J Viral Hepat. 2012 April; 19(4): 271–277. |
[9] | Butt, AA, Xiaoqiang, W., Budoff, M., Leaf, D., Kuller, LH, Justice, AC. (2009).HepatitisC virus and the risk of coronary disease. Clin Infect Dis; 49:225-232. |
[10] | Bukh, J., Miller, RH., Purcell, RH., (1995).Biology and genetic heterogeneity of hepatitis C virus. Clin Exp Rheumatol. Nov- Dec;13 Suppl 13:S3-7. |
[11] | Di Bisceglie AM, Stoddard AM, Dienstag JL, et al.,(2011). Excess mortality in patients with advanced chronic hepatitis C treated with longterm peginterferon. Hepatology; 53(4):1100-1108. |
[12] | Lengyel G, Aszalos Z, Tulassay Z. (2007). Hepatitis C viral infection and depression. Orv Hetil. Jan 7; 148(1):11-5. |
[13] | Darwish, N.M., abas, M.o., Abdel Fattah, M.F. and Darwish, M.A. (1992). Hepatitis C virus infection in blood donoers in Egypt. The journal of Egyptian public health association vol. LXV II, No.34, page 224-232. |
[14] | Osman E E, Esmat G, Adela M G, et al., (2011). Factors affecting recurrence of hepatitis C virus in adult living donor liver transplantation among egyptian patients. Macedonian Journal of Medical Sciences doi:10.3889/MJMS.1857-5773.2011.0144. |
[15] | Suman B S, Seema G, Abhinav V and Sridhar D, (2008). Hs-CRP and oxidative stress in young cad patients: a pilot study. Indian Journal of Clinical Biochemistry, / 23 (4) 334-336. |
[16] | Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis. 2006; 43:e53–6. |
[17] | Rodriguez-Inigo E, Casqueiro M, Bartolome j, et al. (2000). Detection of hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases. J viral Hepat; 7:23-29. |
[18] | Isaguliants MG. (2003). Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy. Curr Pharm Biotechnol; 169-183. |
[19] | Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. (2006). Myocarditis and heart failure associated with hepatitis C virus infection.J Card Fail; 12: 293 – 298. |
[20] | Siagris D, Christofidou M, Theocharis GJ, et al., (2006). Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J. Viral Hepat. Jan; ; 13: 56–61. |
[21] | Dai, CY, Chuang, WL., Hsieh, MY., et al.,(2008).Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. Jul; 49(1):9-16. |
[22] | Judith I T, Mary A W, Alexander M, et al.,(2009). Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease. J Card Fail. June; 15(5): 451–456. |
[23] | Lao XQ, Thompson A, McHutchison JG, McCarthy JJ (2010). Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. J Viral Hepat. Jul 19. |
[24] | Kaptoge S, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010; 375(9709):132–140. |
[25] | Memon L, Spasojevi-Kalimanovska V, Bogavac-Stanojevi N, et al, (2006). Association of C-reactive protein with the presence and extent of angiographically verified coronary artery disease. Tohoku J Exp Med. Jul; 209(3):197-. |
[26] | Huang CF, Hsieh MY, Yang JF, et al., (2010). Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. Hepatol Int. Aug 4; 4(3):621-7. |
[27] | Lidija PD, Maja J, Miodrag V, et al., (2010). High sensitivity C-reactive protein as prediction factor of disease progression in patients with chronic hepatitis C and mild liver steatosis.Acta Medica. Medianae, Vol.49 (3). |
[28] | Nascimento MM, Bruchfeld A, Suliman ME, , et al.(2005).Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. Braz J Med Biol Res; 38:783 - 788. |
[29] | Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, et al. (2001).C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis.Circulation; 104:63-67. |
[30] | Karantza MV, Mittelman SD, Dorey F, et al., (2008).Relationship of highly sensitive C-reactive protein and lipid levels in adolescents with type 1 diabetes mellitus. Pediatr Diabetes.; 9(2):122-6. |
[31] | Sabeti S, Exner M, Mlekusch W, et al.( 2005). Prognostic impact of fibrinogen in carotid atherosclerosis:Nonspecific indicator of inflammation or independent predictor of disease progression? Stroke l; 36: 1400-- 1404. |
[32] | Nikolaos P, Dimitris T, Gerasimos S, Christodoulos S (2010). Is fibrinogen a marker of inflammation in coronary artery disease? Hellenic J Cardiol; 51: 1-9. |
[33] | Gil M, Zarebi إ „ski M, Olszewski R, Adamus J. (2000).Fibrinogen serum levels in patients with stable coronary artery disease and acute coronary syndrome. Pol Merkur Lekarski. Aug; 9(50):531-2. |
[34] | Alyan, O., Kacmaz F., Ozdemir, O., et al., (2008).Hepatitis C infection is associated with increased coronary artery therosclerosis defined by modified Reardon severity score system. Circ J. Dec; 72(12):1960-5. |
[35] | Saatea A, Taufeeq A M, Anjum Z, et al., (2006). Serum sialic acid and fibrinogen in complicated and uncomplicated cirrhosis. Journal of Medical Sciences January, Vol. 14, No. 1. |
[36] | Tuncer Ö, Selahattin A, Hasan A (2011). Correlation of high sensitive C-reactive protein and Hepatitis C Virus RNA in anti-HCV-positive sera Dicle Tıp Dergisi; 38 (2): 134-136. |
[37] | Radkowski M, Wilkinson J, Nowicki M, et al., (2002).Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. Jan; 76(2):600-8. |
[38] | Boddi M, Abbate R, Chellini B, et al., (2010). Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. Jan; 47(1):72-5. |
APA Style
Amin M. Abdel Baki, Nashwa A. Zaky. (2014). Hepatitis C-Virus Infection and Risk of Coronary Heart Diseases. Clinical Medicine Research, 3(2), 44-49. https://doi.org/10.11648/j.cmr.20140302.18
ACS Style
Amin M. Abdel Baki; Nashwa A. Zaky. Hepatitis C-Virus Infection and Risk of Coronary Heart Diseases. Clin. Med. Res. 2014, 3(2), 44-49. doi: 10.11648/j.cmr.20140302.18
@article{10.11648/j.cmr.20140302.18, author = {Amin M. Abdel Baki and Nashwa A. Zaky}, title = {Hepatitis C-Virus Infection and Risk of Coronary Heart Diseases}, journal = {Clinical Medicine Research}, volume = {3}, number = {2}, pages = {44-49}, doi = {10.11648/j.cmr.20140302.18}, url = {https://doi.org/10.11648/j.cmr.20140302.18}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20140302.18}, abstract = {Background: The world Health Organization has declared hepatitis C a global health problem, with approximately 3 % of the worldﹶs population. HCV infection was associated with a high risk of CHD. Hs-CRP and fibrinogen was considered as markers of coronary artery disease, their elevation correlated with incidence of CAD, However Apo A deficiency predict future risk of CAD. Aim: To study correlation between HCV infections and marker risk factors of coronary heart disease in different stages of liver disease. Patients & Method: Forty three chronic HCV patients were recruited at specialized hepatology clinic in National Hepatology and Tropical Medicine Research Institute (NHTMRI),Cairo; they were classified into 3 groups according to Child – Pugh score (A, B, C), 42 % were Child class A, 28 % Child B and 30 % Child C, age from 20 to 80 years. 15 healthy subjects served as control group. Detection of the following tests occurred for both groups: Liver function tests: ALT, AST, ALP, total protein, albumin, bilirubin, GGT and AFP. Ultra sensitive CRP, fibrinogen, apoprotein A and Lipid profile: Total Cholesterol, triglyceride, HDL-C, LDL-C, and Total Lipid. Results: the data obtained from results show that :liver enzymes AST, ALT, total bilirubin, albumin, total protein and INR levels were significantly different between groups and control (p 0.05). Cardiac enzymes; CK and LDH levels were not significantly different between groups and control (p> 0.05). The APO A levels were not differs significantly in study groups and controls (p> 0.05). The fibrinogen andhs-CRP levels in the patients appeared to be significantly higher than those in the healthy controls (p< 0.05). Conclusion: hs-CRP and fibrinogen may be considered as a CHC progression prognostic factor, Evidence indicates that hepatitis C virus (HCV) have a key role in coronary heart disease.}, year = {2014} }
TY - JOUR T1 - Hepatitis C-Virus Infection and Risk of Coronary Heart Diseases AU - Amin M. Abdel Baki AU - Nashwa A. Zaky Y1 - 2014/04/10 PY - 2014 N1 - https://doi.org/10.11648/j.cmr.20140302.18 DO - 10.11648/j.cmr.20140302.18 T2 - Clinical Medicine Research JF - Clinical Medicine Research JO - Clinical Medicine Research SP - 44 EP - 49 PB - Science Publishing Group SN - 2326-9057 UR - https://doi.org/10.11648/j.cmr.20140302.18 AB - Background: The world Health Organization has declared hepatitis C a global health problem, with approximately 3 % of the worldﹶs population. HCV infection was associated with a high risk of CHD. Hs-CRP and fibrinogen was considered as markers of coronary artery disease, their elevation correlated with incidence of CAD, However Apo A deficiency predict future risk of CAD. Aim: To study correlation between HCV infections and marker risk factors of coronary heart disease in different stages of liver disease. Patients & Method: Forty three chronic HCV patients were recruited at specialized hepatology clinic in National Hepatology and Tropical Medicine Research Institute (NHTMRI),Cairo; they were classified into 3 groups according to Child – Pugh score (A, B, C), 42 % were Child class A, 28 % Child B and 30 % Child C, age from 20 to 80 years. 15 healthy subjects served as control group. Detection of the following tests occurred for both groups: Liver function tests: ALT, AST, ALP, total protein, albumin, bilirubin, GGT and AFP. Ultra sensitive CRP, fibrinogen, apoprotein A and Lipid profile: Total Cholesterol, triglyceride, HDL-C, LDL-C, and Total Lipid. Results: the data obtained from results show that :liver enzymes AST, ALT, total bilirubin, albumin, total protein and INR levels were significantly different between groups and control (p 0.05). Cardiac enzymes; CK and LDH levels were not significantly different between groups and control (p> 0.05). The APO A levels were not differs significantly in study groups and controls (p> 0.05). The fibrinogen andhs-CRP levels in the patients appeared to be significantly higher than those in the healthy controls (p< 0.05). Conclusion: hs-CRP and fibrinogen may be considered as a CHC progression prognostic factor, Evidence indicates that hepatitis C virus (HCV) have a key role in coronary heart disease. VL - 3 IS - 2 ER -